Literature DB >> 22342642

Interferon-α (IFNα) neurotoxicity.

Cari Fritz-French1, William Tyor.   

Abstract

Clinical studies indicate that increased central nervous system (CNS) interferon-alpha (IFNα) is associated with cognitive dysfunction in a wide variety of conditions. This has perhaps been best studied in HIV-associated neurocognitive disorders (HAND). These findings on IFNα neurotoxicity have been corroborated in animal studies. Probably the best demonstration of the neurotoxicity of IFNα was through the use of a mouse model of HAND, where it was shown that blocking IFNα with neutralizing antibodies prevented behavioral deficits and associated histopathological effects. In vitro studies have demonstrated a dose dependent, detrimental effect of IFNα on neuronal dendrites. Development of therapeutics that block IFNα may prove to be an effective treatment of HAND and other inflammatory conditions where there is increased CNS IFNα. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342642     DOI: 10.1016/j.cytogfr.2012.01.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  23 in total

1.  Homeostatic interferon expression in neurons is sufficient for early control of viral infection.

Authors:  Sarah E Cavanaugh; Alicia M Holmgren; Glenn F Rall
Journal:  J Neuroimmunol       Date:  2014-12-16       Impact factor: 3.478

2.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

3.  Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis.

Authors:  Coraline Canivet; Chantal Rhéaume; Manon Lebel; Jocelyne Piret; Jean Gosselin; Guy Boivin
Journal:  J Neurovirol       Date:  2018-08-09       Impact factor: 2.643

Review 4.  HIV Eradication Strategies: Implications for the Central Nervous System.

Authors:  Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

5.  Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Authors:  Albert M Anderson; Jeffrey L Lennox; Mark M Mulligan; David W Loring; Henrik Zetterberg; Kaj Blennow; Cari Kessing; Rajeth Koneru; Kirk Easley; William R Tyor
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

6.  Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model.

Authors:  Rajeth Koneru; M Foster Olive; William R Tyor
Journal:  J Neurovirol       Date:  2014-01-11       Impact factor: 2.643

Review 7.  Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection.

Authors:  Lynn Pulliam
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

Review 8.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

9.  Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.

Authors:  Elzbieta Jacek; Brian A Fallon; Abhishek Chandra; Mary K Crow; Gary P Wormser; Armin Alaedini
Journal:  J Neuroimmunol       Date:  2012-11-08       Impact factor: 3.478

10.  Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence.

Authors:  Maria J Polyak; Pornpun Vivithanaporn; Ferdinand G Maingat; John G Walsh; William Branton; Eric A Cohen; Rick Meeker; Christopher Power
Journal:  FASEB J       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.